Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4191 - Menopausal status on tumour biology in early breast cancer


10 Oct 2016


Poster display


Olubukola Ayodele


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


O. Ayodele1, I. Ali1, A. Konenko1, L. Duggan1, N. O'Mara1, R. Rahman2, Y. Ged1, P. Calvert3, A. Horgan1, M. O'Connor1

Author affiliations

  • 1 Medical Oncology, University Hospital Waterford, x91 er8e - Waterford/IE
  • 2 Medical Oncology, St Vincents University Hospital, Dublin/IE
  • 3 Medical Oncology, University Hospital Waterford, Waterford/IE


Abstract 4191


Breast cancer (BC) is primarily a disease of older or post menopausal women. It has been suggested that BC arising in young women is a unique biological subset characterized by less hormone sensitivity and higher HER2 (epidermal growth factor receptor) expression. This study was performed to compare the tumour biology between pre menopausal (PrM) and post menopausal (PoM) women.


New diagnosis of early BC from 2011-2015 in the South East Cancer Centre were included. The patients were divided into PrM (


Data from 497 patients were obtained. 235 (47.3%) were PrM and 262 (52.7%) were PoM. Age range PrM group vs PoM group (29-54 vs 55-91). The differences between the groups was statistically significant on pathology subtype (p = 0.003), T stage (p = 0.033), and N stage (p = 0.008). Ki67 and grade were not statistically significant. The mean ki67 across biology subtypes (ER/PR/HER2/Ki67) in the PrM group was higher. PrM group had more grade III disease (33.2% vs 30.9%). Table 1: Distribution of tumour biology according to menopausal status.

Pre Menopausal n = 235 Post Menopausal n = 262 P value
Age Range 29-54 55-91  


Pre menopausal women in this Irish population had poorer tumour biology compared to their Post menopausal counterpart. Aggressive measures should be taken in the treatment of these women to reduce the incidence of local recurrence and metastases.

Clinical trial identification


Legal entity responsible for the study

University Hospital Waterford


University Hospital Waterford


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.